Cargando…
584. Phase 1 Placebo-Controlled Trial of COVI-VAC™, an Intranasal, Live Attenuated COVID-19 Vaccine
BACKGROUND: COVI-VAC(TM) is an intra-nasal live-attenuated SARS-COV-2 synthetic viral vaccine being developed for the prevention of COVID-19. COVI-VAC is attenuated through deletion of the furin cleavage site and introduction of 283 silent deoptimizing mutations that maintain viral amino acid sequen...
Autores principales: | Tasker, Sybil, Bendel, Daryl, Bevan, Melissa, Mueller, Steffen, Kushnir, Anna, Londt, Brandon, Robert Coleman, J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644858/ http://dx.doi.org/10.1093/ofid/ofab466.782 |
Ejemplares similares
-
577. COVI-VAC™, a Live Attenuated COVID-19 Vaccine, Provides Single Dose Protection Against Heterologous Challenge with SARS-CoV-2 Beta (B.1.351) in the Syrian Golden Hamster Model
por: Kushnir, Anna, et al.
Publicado: (2021) -
1938. CoviLiv™, a Novel Intranasal Live-Attenuated COVID-19 Vaccine Candidate, Induces Robust Humoral and Cellular Immunity in First-In-Human Clinical Trial CDX-CoV-001
por: Kaufmann, Johanna K, et al.
Publicado: (2023) -
Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy
por: Wang, Ying, et al.
Publicado: (2021) -
Gam-COVID-Vac, EpiVacCorona, and CoviVac effectiveness against lung injury during Delta and Omicron variant surges in St. Petersburg, Russia: a test-negative case–control study
por: Barchuk, Anton, et al.
Publicado: (2022) -
Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies
por: Kozlovskaya, Liubov I., et al.
Publicado: (2021)